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Albuminuria is a strong predictor of diabetic nephropathy chronic kidney disease outcomes.
Yet, therapeutic albuminuria-lowering has not consistently translated into a reduction in clin-
ical events suggesting the involvement of additional pathogenic factors. Our hypothesis
is that anti-endothelial cell autoantibodies play a role in development and progression in
diabetic nephropathy. We determined anti-endothelial cell antibody (AECA) bioactivity in
protein A-elutes of baseline plasma in 305 participants in the VA NEPHRON-D study, a ran-
domized trial of angiotensin receptor blocker (ARB) or dual ARB plus angiotensin-converting
enzyme inhibitor therapy in type 2 diabetes with proteinuric nephropathy. Thirty-eight per-
cent (117/305) of participants had significantly reduced endothelial cell survival (≤80%)
in the IgG fraction of plasma. A VA NEPHRON-D primary endpoint [end-stage renal dis-
ease (ESRD), significant reduction in estimated glomerular filtration rate, or death] was
experienced by 58 individuals. In adjusted Cox regression analysis, there was a significant
interaction effect of baseline anti-endothelial cell-mediated cell survival and albuminuria
on the hazard rate (HR) for primary composite endpoint (P =0.017). Participants lack-
ing strongly inhibitory antibodies with albuminuria ≥1 g/g creatinine had a significantly
increased primary event hazard ratio, 3.41 – 95% confidence intervals (CI 1.84–6.33;
P <0.001) compared to those lacking strongly inhibitory antibodies with lower baseline
albuminuria (<1 g/g creatinine). These results suggest that anti-endothelial cell antibodies
interact significantly with albuminuria in predicting the composite endpoint of death, ESRD,
or substantial decline in renal function in older, adult type 2 diabetic nephropathy.
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INTRODUCTION
Diabetic nephropathy is a leading cause of end-stage renal dis-
ease (ESRD) and cardiovascular or all-cause mortality in adults
worldwide (1). Renin–angiotensin system (RAS) activation plays a
central role in the pathogenesis of diabetic nephropathy (2). Block-
ade of the RAS with either an angiotensin-converting enzyme
inhibitor (ACEi) or angiotensin receptor blocker (ARB) lowers
urinary albumin excretion and provides renal protection in dia-
betic nephropathy (2–5). Since dual blockage of the RAS results in
greater albuminuria-lowering than from ACEi or ARB monother-
apy alone (6), the expectation was that albuminuria-lowering per se
may be a goal of treatment in diabetic nephropathy (7). The lack of
demonstrable benefit, however, from dual (ACEi+ARB) therapy
compared to mono-therapy on composite renal or cardiovascular
outcomes in the Ongoing Telmisartan Alone and in Combination
with Ramipril Global Endpoint Trial (ONTARGET) (8) or in the
VA NEPHRON-D study (9) has refocused attention on the need to
identify additional pathogenic factors (besides albuminuria) that
may contribute to clinically important end point occurrences in
diabetic nephropathy.
Endothelial damage and inflammation are among several non-
traditional cardiovascular risk factors implicated in mediating
residual risk in high-risk diabetes mellitus (DM) (10). Increased
retinal and glomerular capillary permeability underlies diabetic
macular edema and albuminuria and vascular permeability is a
hallmark of generalized diabetic vasculopathy (11). In our prior
work, strongly inhibitory endothelial cell (EC) IgG autoantibody
activity was associated with the development of nephropathy in
older adult type 2 DM participants in the Veterans Affairs Dia-
betes Trial (VADT) (12). Since anti-EC antibodies (AECA) in type
2 DM caused strong EC contraction (via Rho A/ROCK signaling
pathway) or apoptosis in vitro (12), we hypothesized that AECA
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may contribute (and/or be a marker for) progression of diabetic
nephropathy. In the current study, we tested whether AECA is asso-
ciated with an increased risk of progression of kidney disease in the
VA NEPHRON-D study (9), a randomized study comparing ARB
or dual ARB plus ACEi therapy in type 2 DM having proteinuric
diabetic nephropathy.
SUBJECTS AND METHODS
STUDY POPULATION
The study population for VA NEPHRON-D has been previously
described. In brief, participants were individuals with type 2
diabetes, urine albuminuria ≥300 mg/g creatinine, and an esti-
mated glomerular filtration (eGFR) rate 30–89.9 ml/min/1.73 m2
(13). Individuals provided informed consent for biorepository
samples at randomization. For the current analysis, a randomly
selected subset of 305 individuals from the 1448 randomized
who had biorepository samples was chosen. The primary end-
point was defined as ESRD, significant reduction in eGFR,
or death. Significant reduction in estimated GFR was defined
as a decline of ≥30 ml/min/1.73 m2 if the initial eGFR was
≥60 ml/min/1.73 m2 or a decline of ≥50% if the initial estimated
GFR was <60 ml/min/1.73 m2.
Overnight fast blood draws were performed at each site. EDTA
plasma was aliquoted and shipped frozen to a central repository
and stored at −80°C. Archived, coded frozen EDTA plasma was
shipped to the laboratory of Dr. Zimering (VA New Jersey Health
Care System, Lyons, NJ, USA) where EC bioassays were performed.
The samples were kept frozen (−40°C) prior to assay for protein
A-eluted EC bioactivity. EC bioactivity in the protein A eluates of
plasma was previously shown to be stable for 5 years or longer at
−20°C (14).
LABORATORY AND CLINICAL MEASURES
Comorbidity was determined using chart review and patient his-
tory; race and ethnicity were by self-report. Cardiovascular disease
is defined as the prior occurrence of any one of the following at
the baseline study evaluation visit (myocardial infarction, coro-
nary revascularization, amputation, peripheral vascular disease,
congestive heart failure, cerebrovascular event). Standard labora-
tory and clinical measures were determined at individual study
sites. Creatinine value for the primary endpoint was measured
in a central lab using an IDMS traceable creatinine assay. Esti-
mated GFR was calculated using the Modification of Diet in Renal
Disease (MDRD) formula for IDMS traceable creatinine. Urinary
albumin excretion rate was determined in a random sample in the
vast majority of participants.
ENDOTHELIAL CELL AUTOANTIBODIES
Protein A affinity chromatography
Protein A chromatography was carried out as previously described
(14, 15). Four-tenths milliliter aliquots of plasma were adjusted to
pH 8.0 by adding 0.8 mL 100 mmol/L Tris (pH 8). After syringe
filtration to clarify samples, 1 mL was applied to a 1 mL column of
packed protein A beads (Pierce Chemical Co., Rockford, IL, USA)
equilibrated in 100 mmol/L Tris, pH 8.0. The column was washed
and eluted as previously described (15). The eluate fractions con-
taining nearly all the recovered protein were pH neutralized and
stored at 0–4°C. Inhibitory activity in protein A eluate fractions
was unchanged, appearing in the retentate fraction after dialysis
(10 mmol/L phosphate, pH 7.4) and ultrafiltration on a 10 kDa
cutoff membrane (Centricon-10; Millipore Corp., Bedford, MA,
USA). All fractions were sterile filtered (Millipore Corp. Bedford,
MA, USA; 0.2 um) before assay for growth-promoting activity.
Protein determinations
Protein concentrations were determined by a bicinchoninic acid
protein assay kit (Pierce Chemical Co., Rockford, IL, USA).
Cell culture and growth assays
Bovine pulmonary artery (BPA) ECs (Clonetics, Inc. San Diego,
CA, USA) were maintained at 37°C in 5% CO2/95% air in Medium
199 plus 10% fetal calf serum. BPA cells were passaged continu-
ously and used between passages 4 and 10. BPA EC (M199, 10%
FCS) were incubated (at 37°C× 48 h) with (30µg/mL) of the
protein A eluate of plasma. BPA ECs mitogenicity is exquisitely
sensitive to low concentrations of basic fibroblast growth factor
(bFGF) (16). We chose BPA ECs in order to permit sensitive detec-
tion of a dynamic range of stimulatory of inhibitory EC activity
in the protein A eluates of plasma. In our prior studies, BPA ECs
proliferated in response to high MW, FGF-like substances in dia-
betic micro- or albuminuric plasma and/or urine (17) and could
be inhibited or stimulated by the protein A eluates from certain
cancer sera (14).
Colorimetric estimation of cell number
Endothelial cell number assays were carried out as previously
reported (15). Confluent cells were trypsinized and plated at 1
to 10× 103 cells/well in Medium 199 plus 10% fetal calf serum
in 96-well plates. After 1 or 2 days incubation for cells to reach
60–80% confluency, test fractions (30µg/mL of protein A eluates
of plasma) were added to wells in quadruplicate. After 48 h incu-
bation in the presence of test fractions, cells were washed with
PBS and processed for the colorimetric estimation of cell num-
ber, i.e., cell-associated acid phosphatase activity, as previously
described (14). There was a linear relationship between EC num-
ber and optical density at 410 nm as previously described (14).
Growth-promoting activity is expressed as a percentage of the
control cell number for cells grown in the absence of test protein
A-eluate fractions. Antibody-mediated cell survival was defined as
the proportion of surviving EC compared to cells without test
IgG (100%). Strongly inhibitory antibody activity (i.e., ≤80%
EC survival) corresponds to anti-EC antibody-mediated survival
previously observed to correlate with the subsequent risk for pro-
gression to diabetic nephropathy (12). Each point represents the
mean of quadruplicate determinations. The intra- and inter-assay
coefficients of variation were 4 and 6% at 1:50 dilution of protein
A-eluted fractions from plasma of three diabetic patients (n= 2–4
assays in each patient).
STATISTICAL ANALYSIS
Student’s t -test or Chi-square test was used for the comparisons
between antibody groups shown in Table 1. Cox regression was
used to model possible baseline risks factors associated with time
to first post-randomization occurrence of the primary compos-
ite endpoint. Both treatment group (losartan monotherapy or
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Table 1 | Participant characteristics at baseline by anti-endothelial cell antibody-mediated cell survival group.
AECA-mediated cell survival (≤80%)*
Overall (n=305) Yes (n=117) No (n=188) P -value
Age (year) 65.3±8.4 66.3±8.8 64.6±8.0 0.09
Hispanic (%) 24 (7.9) 10 (8.5) 14 (7.4) 0.73
Non-Hispanic White (%) 205 (67.2) 81 (69.2) 124 (66.0) 0.55
African American (%) 70 (23.0) 23 (19.7) 47 (25.0) 0.28
BMI (kg/m2) 34.6±6.9 34.6±7.0 34.7±6.8 0.94
Systolic BP (mm Hg) 136.9±15.3 137.4±14.1 136.7±16.0 0.69
Diastolic BP (mm Hg) 73.0±10.2 73.5±10.8 72.7±9.7 0.55
Creatinine, mg/dl geometric mean (95% CI) 1.4 (1.4–1.5) 1.4 (1.3–1.5) 1.4 (1.4–1.5) 0.97
eGFR, ml/min/1.73m2 55.2±18.8 55.1±18.5 55.2±19.0 0.97
Urine albumin/creatinine,/g, median (95% CI) 1501 (466, 1824) 1579(420, 2220) 1452(481, 1696) 0.51
HbA1c, % 7.8±1.2 7.8±1.3 7.8±1.2 0.95
LDL cholesterol (mg/dl) 82.7±33.7 83.0±33.7 82.5±33.8 0.91
Current smoker (%) 65 (21.3) 22 (18.8) 43 (22.9) 0.40
H/O macrovascular event (%) 184 (60.3) 62 (53.0) 122 (64.9) 0.04
Diabetic retinopathy (%) 137 (44.9) 62 (53.0) 75 (39.9) 0.03
Peripheral neuropathy (%) 166 (54.4) 106 (56.4) 166 (54.4) 0.38
Autonomic neuropathy (%) 12 (3.9) 9 (4.8) 12 (3.9) 0.33
Atrial fibrillation (%) 28 (9.2) 15 (12.8) 13 (6.9) 0.08
Use of insulin (%) 210 (68.8) 126 (67.0) 210 (68.9) 0.38
Use of statin (%) 258 (84.6) 158 (84.0) 258 (84.6) 0.74
Use of diuretic (%) 219 (71.8) 134 (71.3) 219 (71.8) 0.80
*Proportion of surviving endothelial cells after 48 h incubation with anti-endothelial cell antibody (AECA) as described in the section “Subjects and Methods.” H/O –
history of; LDL – low density lipoprotein, IQR – interquartile range, BMI – body mass index, eGFR – estimated glomerular filtration rate, BP – blood pressure,
HbA1c – glycosylated hemoglobin.
losartan plus lisinopril), and the stratification variables (baseline
eGFR <60 vs. ≥60), baseline albuminuria (<1 vs. ≥1 g/g creati-
nine) were included as covariates in the model when testing for
an effect of AECA-mediated cell survival (≤80% vs. >80%). In
univariate regression analysis, other risk variables [age, HbA1c,
systolic or diastolic blood pressure, low density lipoprotein (LDL)
cholesterol concentration, and BMI] were tested for association
with time to primary endpoint, and were included in the model
if it reached 0.05 of significance level. Two way-interactions were
checked among treatment, albuminuria, AECA-mediated cell sur-
vival, eGFR, age, and prior macrovascular disease one by one due
to a limited number of events.
P-values for all outcomes were two-sided; values <0.05 were
considered statistically significant. Statistical analyses were per-
formed using SAS, version 9.3.
RESULTS
ASSOCIATION BETWEEN ENDOTHELIAL CELL AUTOANTIBODIES AND
BASELINE RISK FACTORS
All of the 305 individuals in this analysis were men. The study pop-
ulation (n= 305) did not differ significantly in any of the mean
baseline risk factor levels shown in Table 1 from all 1448 random-
ized VA NEPHRON D participants (data not shown). The median
albuminuria level in the 305 individuals was 1501 mg/g creati-
nine, the mean estimated glomerular filtration rate (eGFR) was
55.2± 18.8 ml/min/1.73 m2. We observed 38% (117/305) strongly
inhibitory EC activity (≤80% cell survival) in the immunoglob-
ulin G (IgG) fraction of plasma. Table 1 shows the participant
characteristics by AECA-mediated cell survival group. There was
no significant association between AECA-mediated cell survival
group with baseline kidney function or albuminuria, glycosy-
lated hemoglobin (HbA1c), LDL cholesterol, systolic or diastolic
blood pressure, smoking, or medication use. We observed that
participants with less inhibitory AECA were younger. Individ-
uals with strongly inhibitory AECA were more likely to have
diabetic retinopathy, but less likely to have a history of a prior
macrovascular event. There was a trend of a significant asso-
ciation between strongly inhibitory AECA and baseline atrial
fibrillation history.
RISK FACTORS ASSOCIATED WITH PRIMARY COMPOSITE RENAL
ENDPOINT OCCURRENCES (DEATH, ESRD, SUBSTANTIAL DECLINE IN
eGFR)
Fifty-eight primary end points were experienced by the 305
participants. In Cox regression analysis, there was a significant
interaction effect of baseline AECA-mediated cell survival and
baseline albuminuria level on the hazard rate (HR) for primary
composite endpoint occurrence (P = 0.017) (Table 2). Com-
pared to reference participants with low baseline albuminuria
level (<1 g/g creat) and lacking strongly inhibitory anti-EC anti-
bodies (>80% cell survival), patients with albuminuria >1 g/g
and lacking strongly inhibitory anti-EC antibodies (>80% cell
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survival) had a significantly higher hazard for the primary end-
point, HR, 3.41 (CI, 1.84–6.33; P < 0.001); whereas participants
with strongly inhibitory antibodies and higher baseline albumin-
uria (≥1 g/g creatinine) or those with strongly inhibitory anti-
bodies and lower baseline albuminuria (<1 g/g creatinine) had
a non-significant hazard for primary endpoint occurrence HR,
1.44 (CI, 0.63–3.28) and HR, 1.53 (CI, 0.72–3.27), respectively
(Figure 1; Table 2).
There was no significant association of time to first post-
baseline primary end point occurrence with treatment (P= 0.312),
baseline eGFR (<60 vs. ≥60 mL/min/1.73 m2) (P = 0.580),
prior macrovascular event (P = 0.388) or age (P = 0.078)
(Table 2). There was no significant association of base-
line albuminuria× eGFR, baseline albuminuria× age, baseline
albuminuria× treatment, or baseline AECA-mediated cell sur-
vival× treatment to time to primary endpoint.
Table 2 | Cox regression models of risk factors associated with primary
endpoint.
Parameter Hazard
ratio
Lower
95% CI
Upper
95% CI
P-value
Treatment (ARB+ACEI
vs. ARB alone)
0.78 0.48 1.27 0.312
Albuminuria (<1 g/g)
AECA cell survival ≤80% 1.53 0.72 3.27 0.271
AECA cell survival >80% 1
Albuminuria (≥1 g/g)
AECA cell survival ≤80% 1.44 0.63 3.28 0.385
AECA cell survival >80% 3.41 1.84 6.33 <0.001
GFRLT60 (< 60 vs. ≥60) 1.16 0.69 1.96 0.580
Age 0.97 0.94 1.00 0.078
Prior macrovascular event 0.80 0.49 1.32 0.388
GFRLT – glomerular filtration rate <60 ml/min/1.73 m2.
In Cox regression analysis that did not include albumin-
uria×ACEA-mediated cell survival interaction, there was a sig-
nificant albuminuria effect on the primary endpoint: [HR, 2.25;
95% confidence intervals (CI), 1.37–3.69; P = 0.001] (not shown
in Table 2).
ASSOCIATION BETWEEN AECA-MEDIATED CELL SURVIVAL AND
PRIMARY ENDPOINT BY TREATMENT GROUP AND BASELINE
ALBUMINURIA
We next examined the association between AECA-mediated cell
survival and primary endpoint occurrence in the two treatment
groups stratified by baseline albuminuria level (Table 3). Among
participants having baseline albuminuria level <1 g/g creatinine,
a primary endpoint occurrence was experienced by 19% of ARB-
treated and 17% of ACEi+ARB-treated participants. Among
patients having baseline albuminuria level ≥1 g/g creatinine, a
primary endpoint occurrence was experienced by 29% of ARB-
treated and 25% of ACEi+ARB-treated participants (P = 0.08
compared to lower albuminuria subgroups) (Table 3). In the
higher baseline albuminuria subgroup (≥1 g/g creatinine) pri-
mary endpoint occurrences were experienced by 19% of ARB-
treated patients having AECA-mediated cell survival ≤80 and
38% of ARB-treated patients having AECA-mediated cell survival
>80% (Table 3). Primary endpoint occurrences were experi-
enced by 8% of ACEi+ARB-treated individuals having AECA-
mediated cell survival ≤80 and 35% of ACEi+ARB-treated par-
ticipants having AECA-mediated cell survival >80%, in the high
albuminuria subgroup (Table 3).
DISCUSSION
The present data are the first to suggest a substantially increased
prevalence (38%) of strongly inhibitory plasma anti-EC autoan-
tibodies in proteinuric adult type 2 diabetic nephropathy. These
findings are consistent with prior reports of an association between
strongly inhibitory EC autoantibodies and proteinuric type 2
diabetic nephropathy (12, 18). Taken together, they suggest that
FIGURE 1 | Hazard ratio of time to primary endpoint occurrence by
AECA-mediated cell survival, albuminuria subgroup is shown. The hazard
ratio (bar height) and 95% confidence intervals (brackets) were computed
from Cox regression survival analysis of time to first post-randomization
primary endpoint occurrence using albuminuria <1 g/g creatinine,
AECA-mediated cell survival >80% as the (Ref) – reference group.
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Table 3 | Association between anti-endothelial cell antibody-mediated cell survival group and primary endpoint by treatment and baseline
albuminuria group.
Treatment AECA cell surv. ≤80% AECA cell surv. >80% Total
N No. of prim
endpoint
% N No. of prim
endpoint
% N No. of prim
endpoint
%
ALBUMINURIA
<1 g/g creat ARB alone 26 5 19 55 10 18 81 15 19
ACEI+ARB 29 7 24 48 6 13 77 13 17
Subtotal 55 12 22 103 16 16 158 28 18
≥1 g/g creat ARB alone 36 7 19 42 16 38 78 23 29
ACEI+ARB 26 2 8 43 15 35 69 17 25
Subtotal 62 9 15 85 31 36 147 40 27a
aP=0.08 compared to primary (prim) endpoint occurrence (subtotal) in lower albuminuria subgroup.
strongly inhibitory anti-EC autoantibodies correlate with (and
may have a pathogenic role) the development of nephropathy in
the older adult type 2 DM.
Several of the known properties of anti-EC antibodies sug-
gest their possible involvement in mediating one or more patho-
logical findings [loss of podocytes, loss of glomerular ECs, or
decreased vascular endothelial cell growth factor (VEGF) expres-
sion] reported in renal biopsy specimens in human diabetic
nephropathy (19). For example, the antibodies exhibited high
affinity binding to heparin Sepharose columns (20), binding to
heparan sulfate proteoglycan (HSPG) (18) and were significantly
associated with low or undetectable plasma bFGF (20) and with
increased albuminuria level in diabetic subsets having one or more
microvascular complications (18). Since glomerular loss of HSPG
precedes the development of diabetic albuminuria (21), anti-EC
antibodies, which can target HSPG or HSPG–heparin-binding
growth factor (HBGF) complexes in tissue(s) or plasma may inter-
fere with HBGF-mediated function(s), e.g., survival-promotion
in podocytes or in glomerular capillary ECs mediated by VEGF
and/or bFGF, respectively (22). In addition, strongly inhibitory
anti-EC antibodies induced EC apoptosis and caused strong EC
contraction by activating the RhoA/Rho kinase (ROCK) signaling
pathway in ECs (12). The RhoA/ROCK signaling pathway plays
a key role in mediating EC barrier function (23) and its activa-
tion has been implicated in pathophysiology in animal models
of proteinuric diabetic nephropathy (24). The current finding of a
significant association between potent inhibitory EC autoantibod-
ies and higher baseline prevalence of retinopathy is consistent with
prior reports of an association between anti-EC inhibitory autoan-
tibodies and coexisting diabetic microvascular complications, such
as macular edema, nephropathy, and painful neuropathy (15, 18).
Strongly inhibitory anti-EC, diabetic antibodies may play a role in
a subset of diabetic complications, which share increased capillary
permeability as an underlying mechanism.
Angiotensin II increases bFGF and transforming growth fac-
tor beta (TGF-β) expression in vascular smooth muscle cells
(25); bFGF and TGF-β (acting separately or coordinately) pro-
mote several of the key cellular processes underlying glomeru-
losclerosis and/or tubulointerstitial fibrosis, which are thought to
underlie declining renal function in diabetic nephropathy (20,
26–28). Although bFGF does not normally circulate in normal
adult, non-pregnant plasma, its levels increased substantially in
diabetic micro- and macroalbuminuria (29) and were signifi-
cantly associated with increased plasma plasminogen activator
inhibitor-1 (29), an important mediator in diabetic glomeruloscle-
rosis (30). The present finding of a significant inverse association
between strongly inhibitory anti-EC antibodies and the HR for
primary composite endpoint in VA NEPHRON-D participants
with higher baseline albuminuria is consistent with a role for
decreased local tissue bioavailability of bFGF (in association with
strongly inhibitory anti-EC antibodies) as was previously reported
in subsets of older adult type 2 DM (12, 15, 18).
Less inhibitory and/or stimulatory anti-EC antibodies (which
together encompass AECA-mediated cell survival >80%) may be
a marker involved in mediating the increased hazard for primary
endpoint in patients having higher albuminuria. Prior work in
older adult type 2 DM (31) and in cancer subsets (14) demon-
strated that less inhibitory anti-EC antibodies frequently coexisted
with increased bFGF and with a pool of high titer (FGF-like)
growth stimulatory antibodies. In a preliminary investigation in
a cohort with more advanced baseline type 2 DM CKD (eGFR
ranging from 15 to 25 ml/min/1.73 m2) than in the baseline VA-
NEPHRON-D, participants were 2.5 times more likely to have had
(low titer) weakly inhibitory and (high titer) moderately stimu-
latory (FGF-like) EC plasma antibodies (i.e., AECA >80%) than
AECA ≤80%, i.e., strongly inhibitory anti-EC antibodies at both
low and high titers tested [M. Zimering,unpublished observation].
Growth stimulatory antibodies having properties resembling those
of bFGF stimulated proliferation in both ECs and in fibroblasts
(14). They may contribute to progression in diabetic nephropa-
thy through actions similar to those of bFGF, which stimulated
fibroblast proliferation in the renal interstitium (28).
The albuminuria× anti-EC antibody-mediated cell survival
interaction demonstrated here suggests that higher albuminuria
is necessary, but may not be sufficient to explain a substantial
degree of the variability in renal composite endpoint occurrence in
an older, high-risk diabetic nephropathy population. Endothelial
damage and inflammation have been identified as possible markers
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of residual high risk in subsets of diabetic nephropathy (10). Basic
FGF is released as a result of endothelial damage (32) and tubu-
lointerstitial inflammation is thought to be mediated in part by
increased albuminuria and by RAS activation (22). Taken together,
bFGF released ectopically as a result of endothelial damage and
pro-inflammatory cytokines upregulated (in part) as a result of
hyperglycemia and/or obesity in type 2 diabetes may facilitate
(through as yet poorly-defined mechanisms) immune interactions
favoring a transition from strongly inhibitory (AECA ≤80%) to
less inhibitory or stimulatory AECA having cell-mediated survival
>80% in subsets of advancing diabetic CKD. Increased expres-
sion of high affinity HSPG binding sites for bFGF reported in the
renal interstitium during tubulointerstitial fibrosis (33) may pro-
vide an additional mechanism for strongly inhibitory or FGF-like
stimulatory autoantibodies to differentially modulate the rate of
tubulointerstitial fibrosis thereby slowing or accelerating, respec-
tively, the rate of decline in renal function in diabetic nephropathy.
Increased glomerular capillary permeability underlies higher albu-
minuria level suggesting that higher albuminuria level facilitates
access to the renal interstitium of IgG present at high titer, i.e.,
strongly inhibitory (in AECA≤80%) or stimulatory IgG (in AECA
>80%), respectively. In this way, local cell proliferation in the renal
interstitium is likely to be modulated by EC autoantibodies occur-
ring near the extremes along a spectrum from strongly inhibitory
to stimulatory EC activity.
Among several limitations of our study, one is that the find-
ings may only reflect the experience of middle-aged or older
men with type 2 DM. More study is needed in additional and
larger diabetic populations to confirm a role for AECA-mediated
cell survival/albuminuria interaction effect on primary endpoint
occurrence. Non-diabetic renal disease may have coexisted in a
small subset of adult type 2 diabetes and possibly contributed to
the observed effect of AECA-mediated cell survival/albuminuria
interaction on the overall rate of primary end point occurrence.
An increased prevalence of anti-EC antibodies was reported in
advanced non-diabetic CKD compared to a normal population
(34) and similar kinds of effects in ECs (e.g., increased cytoso-
lic calcium and actin stress fiber formation) were observed in
autoantibodies from non-diabetic (34) or diabetic CKD autoan-
tibodies (12). Still, we could not determine whether our find-
ings may be generalizable to non-diabetic CKD populations.
More detailed characterization of the diabetic nephropathy IgG
autoantibodies (e.g., its subclass specificity) will also require fur-
ther study. In our preliminary experiments, strongly inhibitory
anti-EC activity was stable after storage (at 0–4°C) for at least
9 months, and addition of 10µg/mL concentrations in three of
three strongly inhibitory anti-EC antibodies tested to EC cells
caused rapid EC contraction (within 1 min) and stress fiber for-
mation. After fourfold dilution (in a subset of the protein A
eluates) from a starting 30µg/mL concentration, mean activity in
protein A eluates in strongly inhibitory anti-EC antibodies still
significantly exceeded mean activity in protein A eluates from
patients having less inhibitory anti-EC antibodies (79.7± 4.9%
vs. 97.3+ 3.4%; p< 0.001, n= 9 patients). The latter observa-
tion is consistent with a possible role for higher titer, strongly
inhibitory anti-EC antibodies in modulating HBGF bioavailability
in the renal interstitium.
In summary, the current findings demonstrate involvement of
a novel, putative pathogenic factor, i.e., anti-EC autoantibodies,
as a significant modulator of the occurrence of the compos-
ite endpoint of renal function decline, ESRD, or death in adult
proteinuric, type 2 DM. Much more study is needed to deter-
mine whether the albuminuria/AECA interaction implies a dual
role for strongly inhibitory and/or stimulatory antibodies asso-
ciated with less inhibitory antibodies in providing a brake for
or accelerating growth factor-driven cellular processes underly-
ing declining renal function (or premature death) in adult type 2
DM nephropathy.
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